Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006 Paris, France.
CHU de Rennes, Department of Anesthesiology Critical Care Medicine and Perioperative Medicine, F-35000 Rennes, France.
Int J Mol Sci. 2020 Feb 19;21(4):1391. doi: 10.3390/ijms21041391.
The P2Y receptor is a key player in platelet activation and a major target for antithrombotic drugs. The beneficial effects of P2Y receptor antagonists might, however, not be restricted to the primary and secondary prevention of arterial thrombosis. Indeed, it has been established that platelet activation also has an essential role in inflammation. Additionally, nonplatelet P2Y receptors present in immune cells and vascular smooth muscle cells might be effective players in the inflammatory response. This review will investigate the biological and clinical impact of P2Y receptor inhibition beyond its platelet-driven antithrombotic effects, focusing on its anti-inflammatory role. We will discuss the potential molecular and cellular mechanisms of P2Y-mediated inflammation, including cytokine release, platelet-leukocyte interactions and neutrophil extracellular trap formation. Then we will summarize the current evidence on the beneficial effects of P2Y antagonists during various clinical inflammatory diseases, especially during sepsis, acute lung injury, asthma, atherosclerosis, and cancer.
P2Y 受体是血小板激活的关键分子,也是抗血栓药物的主要靶点。然而,P2Y 受体拮抗剂的有益作用可能不仅局限于动脉血栓形成的一级和二级预防。事实上,已经证实血小板激活在炎症中也起着至关重要的作用。此外,免疫细胞和血管平滑肌细胞中存在的非血小板 P2Y 受体可能是炎症反应中的有效参与者。本综述将探讨 P2Y 受体抑制作用超出其血小板驱动的抗血栓作用的生物学和临床影响,重点关注其抗炎作用。我们将讨论 P2Y 介导的炎症的潜在分子和细胞机制,包括细胞因子释放、血小板-白细胞相互作用和中性粒细胞胞外诱捕网形成。然后,我们将总结目前关于 P2Y 拮抗剂在各种临床炎症性疾病中的有益作用的证据,特别是在脓毒症、急性肺损伤、哮喘、动脉粥样硬化和癌症中。